Varian Announces CE Mark for Embozene in Genicular Artery Embolisation, Expanding Treatment for Knee Osteoarthritis

Contributed by: Business Wire

Logo

Tags

Radiology

Physical Therapy

Managed Care

Surgery

Oncology

General Health

Health

Health Technology

Varian

More Like This

PR Newswire associated0

Emboline Prevails in German Utility Model Infringement Action Against AorticLab

Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS

Emboline Announces First U.S. Commercial Use of the Emboliner® Embolic Protection System

PR Newswire associated0

Emboline Receives U.S. FDA 510(k) Clearance for Emboliner® Embolic Protection System

U.S. FDA GRANTS LIPOGEMS® SECOND IDE APPROVAL FOR A CLINICAL TRIAL ON THE TREATMENT FOR KNEE OA

World’s First Patients Successfully Treated With Novel Scarcell Therapeutics Therapy Using Gum Cells Designed to Relieve Knee Osteoarthritis

Emboline, Inc. Completes Enrollment in U.S. Pivotal IDE Trial of the Emboliner® Embolic Protection Catheter Designed to Protect Patients from Embolic Injury During Transcatheter Aortic Valve Replacement

Protembis Announces FDA Approval of its Pivotal Investigational Device Exemption (IDE) Study